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Abstract
Microarray data analysis has been shown to provide an effective tool for studying cancer and genetic diseases. Although
classical machine learning techniques have successfully been applied to find informative genes and to predict class labels
for new samples, common restrictions of microarray analysis such as small sample sizes, a large attribute space and high
noise levels still limit its scientific and clinical applications. Increasing the interpretability of prediction models while
retaining a high accuracy would help to exploit the information content in microarray data more effectively. For this
purpose, we evaluate our rule-based evolutionary machine learning systems, BioHEL and GAssist, on three public microarray
cancer datasets, obtaining simple rule-based models for sample classification. A comparison with other benchmark
microarray sample classifiers based on three diverse feature selection algorithms suggests that these evolutionary learning
techniques can compete with state-of-the-art methods like support vector machines. The obtained models reach accuracies
above 90% in two-level external cross-validation, with the added value of facilitating interpretation by using only
combinations of simple if-then-else rules. As a further benefit, a literature mining analysis reveals that prioritizations of
informative genes extracted from BioHEL’s classification rule sets can outperform gene rankings obtained from a
conventional ensemble feature selection in terms of the pointwise mutual information between relevant disease terms and
the standardized names of top-ranked genes.
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Introduction
Gene expression profiling and data analysis is a widely used
approach to gain new insights on the regulation of cellular
processes in biological systems of interest. For this purpose,
common statistical methods and machine learning techniques can
be employed, including clustering methods to discover classes of
related biological samples, feature selection methods to identify
informative genes and classification methods to assign class labels
to cell samples with unknown biological conditions.
Here we focus on supervised gene expression analysis of cancer
microarray data using feature selection and classification methods.
Further progress in the accuracy and interpretability of microarray
classification models is of great practical interest, since a more
accurate cancer diagnosis using microarrays would help to prevent
inappropriate therapy selection.
Although high prediction accuracies have already been reached
on many microarray cancer datasets, the models are often very
complex and difficult to interpret, and lack robustness when being
applied on external data from other experimental platforms.
Specifically, challenges arise from small sample sizes, large
numbers of uninformative genes, high noise levels, several outliers
and systematic bias. While experiments can often be conducted
with high reproducibility within a single laboratory, results
obtained based on different chip technologies and experimental
procedures from different laboratories are often hardly compara-
ble. Some of these issues can be addressed by using cross-study
normalization methods and integrative microarray analysis [1,2]
or by combining microarray data with clinical data [3,4]. To
obtain further improvements, in previous studies we have
employed ensemble learning techniques [5–7] and integrated data
from cellular pathways, co-expression networks and molecular
interactions into the analysis [8–11]. However, there remains a
need for more accurate, robust and easily interpretable prediction
methods.
In order to alleviate some of the typical problems of current
microarray studies and show the benefits of rule-based evolution-
ary machine learning systems for microarray sample classification,
resulting from the capabilities of evolutionary computation and the
enhanced interpretability of decision rules, we evaluate our
previously developed machine learning systems BioHEL [12–15]
and GAssist [16–20] on three large-scale, public microarray
cancer datasets.
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Evolutionary learning methods have already been applied
successfully in different microarray studies, e.g. for selecting
informative subsets of genes [21–23], for clustering and bicluster-
ing [24–26] and sample classification [27–29]. Moreover, in recent
years new rule-based classification approaches were successfully
tested on high-dimensional gene array data [30–33], providing
human-interpretable rule sets as models.
The machine learning systems presented in this paper combine
these two paradigms, evolutionary search and rule learning,
providing both an effective search space exploration and an
enhanced model interpretability. In particular, BioHEL’s con-
junctive rules can point the experimenter to potential functional
association between genes [34], and its value range rules provide
the user with an indication on whether a gene tends to be up- or
down-regulated in the corresponding biological condition, given
the complete value range across all samples. An illustration of the
entire analytical protocol is shown in Fig. 1. First, we normalize
each microarray dataset and pre-filter the attributes to reduce the
dimensionality. Next, we apply our learning algorithms BioHEL
[12–15] and GAssist [16–20] in combination with different feature
selection algorithms using a cross-validation scheme and repeat
this process with three alternative classifiers (see Experimental
protocol). In the last step, the generated prediction results and the
genetic probes (later referred to by their corresponding genes) that
were considered as most informative by the learning system are
analyzed statistically and using a text-mining approach to find
associations between relevant disease terms and corresponding
standardized gene identifiers.
We will discuss these steps in detail according to the following
structure: In the Methods section we provide a step-by-step
description of our experiments and explain each of the used
techniques in detail, dealing first with the feature selection
approaches, then with the machine learning systems BioHEL
and GAssist, and finally with the datasets and pre-processing
methods. The Results section contains the prediction results of
running BioHEL, GAssist and the alternative classifiers on the
three microarray cancer datasets. Moreover, this section presents a
post-analysis of the results using biomedical literature mining. In
the Conclusions section, we provide an outlook on further possible
extensions of the classification framework.
In summary, the overall aim of the study was to obtain more
biologically interpretable models for microarray cancer sample
classification, which enable a robust prioritization of putative
biomarkers and reach competitive prediction accuracies. Instead
of tweaking algorithms or re-developing them from scratch to
maximize accuracy at the cost of higher complexity, the goal was
achieved by a new analysis pipeline that investigates how different
algorithms profit from external feature selection, and that exploits
the known benefits of existing evolutionary algorithms in terms of
search space exploration and exploitation, and of rule-based
learning methods in terms of interpretability.
Methods
Experimental Protocol
Our analysis pipeline to compare both feature selection and
prediction methods for microarray sample classification consists of
three basic steps: Data pre-processing, supervised analysis of the
data and post-analysis of the results.
In the first stage, the microarray datasets are pre-processed and
normalized (see section Datasets). Next, an external cross-
validation is performed [35], i.e. in each cycle of the cross-
validation, first a feature selection method is applied on the current
training data and the resulting subset of features is used to classify
the test set samples with a machine learning method. This
procedure is employed using both 10-fold cross-validation (CV,
with random splits but consistent splits across all comparisons) and
leave-one-out CV (LOOCV) and different combinations of feature
selection and classification algorithms. Specifically, the feature
selection methods include the univariate filter ‘‘Partial-Least-
Squares based Feature Selection’’ (PLSS), the combinatorial filter
‘‘Correlation-based Feature Selection’’ (CFS) [36] and the
embedded feature selection method ‘‘Random Forest based
Feature Selection’’ (RFS, all selection methods are discussed in
detail below). The classification methods include our own methods
BioHEL and GAssist, a support vector machine [37], a Random
Forest classifier (RF) [38] and the ‘‘Prediction Analysis of
Microarrays’’ method (PAM) [39]; see flowchart in Fig. 1.
In the last step of the protocol, we use a literature mining
analysis to compare rankings of informative genetic probes
(referred to as genes in the Results section, because all selected
genetic probes could be mapped to a unique gene identifier via the
mapping information provided by the chip manufacturer),
obtained from classical feature selection methods and from a
post-processing of the rule-based models generated by the BioHEL
approach.
Datasets
All methods are evaluated on three public microarray cancer
datasets representing three different types of cancer: Prostate
cancer (52 tumor samples vs. 50 controls) [40], lymphoma (58
Diffuse large B-cell lymphoma samples vs. 19 follicular lymphoma
samples) [41], and a breast cancer dataset obtained from the
collaborating Queens Medical Centre in Nottingham (84 luminal
samples vs. 44 non-luminal samples) [6,42–44] (see Table 1).
Details for each dataset and pre-processing method used in this
comparative evaluation are provided in the Material S1. All pre-
processed datasets are also available online (http://icos.cs.nott.ac.
uk/datasets/microarray.html), including the cross-validation sub-
sets after feature selection.
Feature Selection Methods
The high number of features (genetic probes) and the relatively
small number of observations (samples) in typical microarray
studies pose various statistical problems, which are known as the
‘‘curse of dimensionality’’ in machine learning (see [45]).
Therefore, after the normalization and pre-filtering of the original
datasets, we apply different feature selection approaches to extract
compact sets of discriminative attributes prior to the application of
classification methods. Moreover, in order to evaluate to which
extent our evolutionary machine learning approaches BioHEL
and GAssist are capable of classifying samples without prior
attribute selection, we evaluate the predictive performance of these
approaches both with and without a dedicated external feature
selection.
To account for the diversity of feature selection methods, three
types of selection approaches are considered separately: A
univariate filter (PLSS [46]), a combinatorial filter (CFS [36])
and an embedded selection approach (RFS [38]). Importantly, we
only consider algorithms which are guaranteed to have a feasible
runtime even on very large datasets, and instead of attempting to
identify all relevant features, we aim at avoiding the selection of
redundant features, which can degrade the classification perfor-
mance (see [47] for a comparison of the all relevant selection
problem against the minimal-optimal selection problem considered
here). For a general review on feature selection approaches in
bioinformatics, please see [48].
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For all feature selection methods the maximum feature subset
size was set to 30 to prevent over-fitting, reduce the model
complexity and the probability of including false positive features
(however, the methods are allowed to flexibly select less than 30
features). This upper bound was chosen according to the results of
studies estimating the approximate number of features to be
selected in different types of microarray studies to obtain only
genetic probes with significant informative value on the outcome
attribute (using different models to compute p-value significance
scores, see [49–51]). The selection methods are described in detail
in the following paragraphs.
Partial-Least-Squares Based Feature Selection (PLSS)
As a representative of a classical univariate filter, a method using
the Partial Least Squares (PLS) [52] algorithm is employed.
Specifically, the features are ordered by the absolute values of the
weight vector defining the first latent component in a PLS model
that was built upon the training data. As previously shown [53],
the ordering of features obtained from this approach is equivalent
to the F-statistic used in analysis of variance (ANOVA). Thus,
instead of the PLS calculation, the F-statistic itself could have been
used, but PLSS provides a more efficient way of performing the
computation (the fast SIMPLS algorithm [54] is used for this
purpose).
Correlation Based Feature Selection (CFS)
The combinatorial filter method CFS [36] searches for subsets
of features that have high correlation to the outcome variable but
low correlation amongst each other. This concept is formalized by
the following feature subset score:
Figure 1. Flowchart illustrating the experimental procedure. The protocol consists of three steps: 1) Pre-processing; 2) Supervised analysis; 3)
Post-analysis.
doi:10.1371/journal.pone.0039932.g001
Table 1. Datasets used in this paper.
Dataset Platform No. of genes No. of samples References
class 1; class 2
Lymphoma Affymetrix 7,129 58 (D); 19 (F) [41]
Prostate Affymetrix 12,600 52 (T); 50 (N) [40]
Breast Illumina 47,293 84 (L); 44 (N) [6,42–44]
doi:10.1371/journal.pone.0039932.t001
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CFS(S)~
k:crfffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
kzk(k{1)cff
p ð1Þ
where S is the selected subset with k features, crf is the average
feature-class correlation and cff the average feature-feature
correlation. While the denominator reduces the score for
correlated features to eliminate redundant variables, the numer-
ator promotes features with high correlation to the class variable to
retain them as powerful discriminators. As proposed in the original
CFS publication, a greedy best-first search strategy was employed
to explore the feature subset space [36].
Random Forest based Feature Selection (RFS)
In contrast to the CFS and the PLSS algorithm, the attribute
selection based on the Random Forest classifier [38] uses a method
directly embedded into the prediction algorithm. Specifically, a
Random Forest model is built by training many binary, unpruned
decision trees on bootstrap sub-samples of the training data. The
importance of a feature can be evaluated based on the Gini index
node impurity measure [55], by calculating the mean decrease in
this measure (MDG) from parent nodes to their direct descendent
nodes over all tree nodes, or alternatively, by the mean decrease in
accuracy (MDA). Different machine learning studies have
obtained different results regarding the comparative robustness
of the MDA and MDG [56,57], but on microarray gene
expression data the results for these two impurity measures have
been observed to be very similar [58]. Thus, only the MDG
criterion will be considered in this study. A feature subset is
obtained from the corresponding attribute ranking by selecting the
top n features (here, n is chosen such that the obtained subset sizes
are comparable to those in the CFS method).
Classification: BioHEL and GAssist
BioHEL (Bioinformatics-Oriented Hierarchical Learning) [12–
15] is an evolutionary machine learning system employing the
Iterative Rule Learning (IRL) paradigm [59,60] (BioHEL’s source
code is available online: http://icos.cs.nott.ac.uk/software/biohel.
html). The IRL procedure begins with an empty rule set and the
complete set of observations as input. Classification rules are
added iteratively to the set of rules until their combination covers
all samples. The final outputs are structured rule sets, also known
as decision lists [61]. A real example rule set obtained on the
prostate cancer dataset is shown in Fig. 2 and highlights the
different rule types in BioHEL: Conjunctive rules, which can provide
information on potential functional associations between genes;
value range rules, which highlight the preferential up- or down-
regulation of genes under different biological conditions and the
robustness for a class assignment in terms of the relative width or
narrowness of an expression value range; and default rules, which
apply if none of the previous specific rules is matched. Each time a
new decision rule has been learnt and added to a corresponding
rule set, the observations it covers are removed from the examples
set.
To explore the search space of possible rules efficiently, BioHEL
uses a standard generational Genetic Algorithm (GA) which is
applied in each IRL iteration to find the best rule for samples
which have not yet been covered by rules found in previous
iterations. Since GAs are non-deterministic, multiple repetitions of
the rule learning process with identical training sets can be used to
increase the probability of finding the optimal rule. Additionally,
repetitions of the complete learning process (i.e. generating a
complete rule set and not just a single rule) can also be applied, in
order to combine several rule sets to a majority-vote consensus
prediction and benefit from the variance-reducing effects of
ensemble learning [62].
In order to find the best rule in each IRL iteration, the fitness
function used in the GA accounts both for the accuracy and the
generality, i.e. the number of covered observations, of a rule. In
BioHEL, this fitness function is based on the Minimum
Description Length (MDL) principle [63] and rewards rules with.
N high accuracy, i.e. rules that classify most samples correctly,
N high coverage, i.e. rules that match many samples, and
N low complexity, i.e. rules with simple predicates.
The exact definition of BioHEL’s fitness function has been
presented and discussed elsewhere [15]. However, as regards the
rule coverage, it is worth mentioning that rules in BioHEL which
cover a certain minimum percentage of observations receive a
high reward, but after surpassing this threshold, the additional
reward for covering more samples is smaller.
BioHEL has been strongly influenced by its predecessor
software GAssist [16–20] (http://icos.cs.nott.ac.uk/software/
gassist.html), from which it has inherited the knowledge represen-
tation. In contrast to the IRL approach employed in BioHEL,
GAssist is a Pittsburgh-style learning classifier system [64], i.e. the
individuals that are evolved in a generational GA are not single
classification rules but rule sets representing complete tentative
solutions of the data mining problem. For the exact definition of
GAssist’s fitness formula, please see [16].
Previous empirical comparisons of BioHEL and GAssist have
shown that GAssist tends to perform better on small datasets,
whereas its successor BioHEL provides superior performance on
large datasets, both in terms of number of instances and/or
number of attributes. Thus, we employ both methods here to
investigate their relative predictive power on microarray data. In
particular, BioHEL was the only predictor for which an
application on microarray data without external feature selection
was possible in a feasible runtime for the LOOCV runs, hence,
this learning method was applied both with and without external
feature selection.
The cross-validation procedure, BioHEL and the alternative
benchmark algorithms and feature selection methods have been
integrated into our publicly available web-based microarray data
analysis software ArrayMining [5].
Evaluation Methods and Implementation Parameters
The main evaluation method used in this study is a cross-
validation scheme known as two-level external cross-validation [35]. In
an external cross-validation, the feature selection algorithm is
applied independently to each training set generated across the
cycles of the validation procedure. This approach avoids the
selection bias of classical internal cross-validation, where feature
selection is only performed once on the whole dataset prior to the
cross-validation [65]. Two-level external cross-validation uses an
additional nested cross-validation to optimize the parameters for
the prediction algorithm using a grid search. We apply this second
level of cross-validation to fit the parameters for the alternative
benchmark predictors SVM, RF, and PAM.
BioHEL is used with the same default parameters as stated in
[15] except for the number of iterations which is set to 500 and the
probabilities for generalization and specialization which are set to
0.5. GAssist is applied using its default parameters [19] except for
the number of iterations which is set to 500 as well. Both GAssist
and BioHEL were run 100 times for each training set with
different random seeds. Each run resulted in a rule set. An
Rule-Based Candidate Disease Gene Prioritization
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ensemble of the resulting 100 rule sets was used to predict the
corresponding test set.
In order to compare BioHEL and GAssist against commonly
used methods for microarray sample classification, the whole
cross-validation procedure was applied to three alternative
benchmark classifiers: A support vector machine (SVM) [37], a
random forest classifier (RF) [38] and the ‘‘Prediction Analysis of
Microarrays’’ method (PAM) [39].
The support vector machine we use is a linear kernel C-SVM
from the e1071-package of the R statistical learning environment,
a wrapper for the well-known LibSVM library. Other polynomial
kernels and the radial basis function kernel were tested without
providing superior results in our experiments (data not shown).
This observation matches well to earlier findings in the literature
according to which linear kernel SVMs often perform similar or
better on microarray data than SVMs using polynomial kernels of
higher degree [66,67]. To employ the RF and PAM method, we
used the corresponding R packages randomForest and pamr which
are both available on the website of the Comprehensive R Archive
Network (CRAN, http://cran.r-project.org).
For the comparison of our method with alternatives from the
literature we only considered approaches using cross-validation for
evaluation, since methods based on a single random training/test
set partition are now widely regarded as unreliable [65]. For the
same reason, we also exclude methods from the literature using
internal cross-validation instead of external cross-validation,
wherever this was clearly stated by the authors.
Since higher-level statistical analysis of microarray data can
depend significantly on the data pre-processing procedure, we
additionally investigate the robustness of the prediction and
feature selection results for different pre-processings applied to the
largest benchmark dataset. New pre-processings were obtained by
using two different fold-change filters and 4 different settings for
the maximum number of selected features, and the entire
analytical protocol was run again for each of these variants. The
stability of the results was analyzed both in terms of the cross-
validated prediction results and the number of shared selected
features across all the CV-cycles (see Material S1 for the results
and discussion of all robustness analyses).
Importantly, the obtained prediction models are only applicable
to samples from the same platform, cell type, environmental
conditions and experimental procedure. However, as our classi-
fiers support both continuous and discretized input data, they are
compatible with most of the cross-study normalization methods
that have been proposed in the literature to extend the
applicability of machine learning models across different experi-
mental platforms (we have previously developed a corresponding
software framework that provides access to several of these cross-
platform integration methods online [5]).
Literature Mining Analysis of Selected Genes
The statistically significant differential expression of genes and
their utility as predictors in a machine learning model for sample
classification can indicate functional associations between these
genes and the biological conditions of the cells under consideration
(strictly speaking, our models use genetic probes instead of genes,
but since we obtained a unique mapping for all selected probes, we
will refer to their corresponding genes in the following). However,
although these information sources are useful for the prioritization
of candidate disease genes in biomedical studies, only experimental
evidence or previous knowledge from the literature can demon-
strate a functional association with the biological conditions of
interest.
One of the most promising candidate genes obtained from our
analysis of the breast cancer dataset was successfully evaluated in
an experimental study in collaboration with the Queen’s Medical
Centre in Nottingham by immunohistochemistry using tissue
microarrays across 1140 invasive breast cancer samples (see our
previous publication [6], the visualization of the dataset in [68],
and the Results section below), however, an experimental
validation of all top-ranked genes across all three microarray
cancer datasets was not within the scope of this study.
Therefore, in order to examine potential associations between
the disease conditions represented by the three datasets and the
informative genes obtained from the feature selection methods and
the most frequently occurring attributes in BioHEL’s rule sets, a
literature mining analysis was applied to these genes using full-text
articles from the PubMed database. Specifically, we scored
Figure 2. A BioHEL classification rule set obtained for the prostate cancer dataset and illustrating different types of rules. ‘‘Exp(x)’’ is
short for ‘‘Expression of gene x’’, where x is a HUGO gene symbol, ‘‘^’’ represents the conjunctive AND-operator, ‘‘[x,y]’’ is an interval of expression
values in which the value of the attribute must lie to fulfill one premise of the rule, and ‘‘-w’’ is a class assignment operator, followed by the output
class of the rule. Rule 5 is a default rule that applies if no rule above is matched.
doi:10.1371/journal.pone.0039932.g002
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putative associations between standardized names of top-ranked
genes and disease terms from a controlled vocabulary (the Medical
Subject Headings (MeSH) disease headings) by determining the
frequency of occurrence and co-occurrence of the corresponding
terms and computing the pointwise mutual information (PMI)
[69]. The PMI of two terms t1 and t2, occurring with relative
frequency f(t1) and f(t2), and co-occurring with relative frequency
f(t1,t2) in a database of documents is defined as follows:
PMI(t1,t2)~log(
f (t1,t2)
f (t1)  f (t2) ) ð2Þ
The specific MeSH disease terms used here were ‘‘prostatic
neoplasms’’ for the prostate cancer dataset, ‘‘breast neoplasms’’ for
the breast cancer dataset, and ‘‘lymphoma, b-cell’’ for the b-cell
lymphoma dataset (PubMed articles are manually annotated by
experts with these and other terms from the MeSH controlled
vocabulary thesaurus). The PMI-value for a pair of gene/disease
terms can thus be used to rank and prioritize potential functional
associations, and similar PMI-based scoring schemes have
previously been used to rank the similarity of genes and drugs
using literature mining [70].
Since the PMI-scores for single gene/disease term pairs are not
reliable enough to compare the utility of different disease gene
prioritizations, we first computed the sum of positive PMI-scores
across all top-ranked genes obtained from either the feature
selection methods or the most frequently occurring attributes in
the BioHEL rules sets. Genes with negative PMI-scores were
considered as irrelevant and the corresponding score was set to
zero, since the magnitude of negative scores is likely subject to
random noise. The final sums of scores were compared against
corresponding scores for 100 randomly selected matched-size gene
sets from the corresponding microarray platforms. P-value
significance scores were estimated by the proportion of times
higher PMI-scores were achieved by the random model in
comparison to the algorithmic selection methods. The top-ranked
genes were defined as those genes that had been selected by at least
two different feature selection methods, (i.e. genes corresponding
to an ensemble selection), which resulted in compact sets of less
than 20 selected attributes for each of the three datasets (see
Results section). The same numbers of genes were selected from
the most frequently occurring features in the BioHEL rules sets in
order to obtain a fair comparison between this BioHEL-based
feature selection and the ensemble feature selection obtained from
the dedicated selection methods.
Results and Discussion
Comparison of Prediction Results
An overview of the comparative prediction results obtained with
all combinations of feature selection, prediction methods and
datasets is given in Table 2 for 10-fold CV and Table 3 for
LOOCV. Below the results for all datasets are discussed.
Table 2. 10-fold cross-validation results.
Dataset
Feature
Selection Classification AVG (%) STDDEV
CFS BioHEL 91 8
CFS GAssist 93 10
CFS SVM 90 10
CFS RF 92 11
CFS PAM 91 10
PLSS BioHEL 92 8
PLSS GAssist 93 9
Prostate cancer PLSS SVM 90 11
PLSS RF 92 9
PLSS PAM 94 8
RFS BioHEL 89 8
RFS GAssist 92 12
RFS SVM 88 8
RFS RF 93 9
RFS PAM 90 11
none BioHEL 94 8
CFS BioHEL 81 10
CFS GAssist 80 15
CFS SVM 87 12
CFS RF 87 16
CFS PAM 78 17
PLSS BioHEL 93 12
Diffuse large PLSS GAssist 94 6
B-cell lymphoma PLSS SVM 91 13
PLSS RF 87 8
PLSS PAM 86 11
RFS BioHEL 91 11
RFS GAssist 89 13
RFS SVM 91 13
RFS RF 89 13
RFS PAM 86 14
none BioHEL 95 8
CFS BioHEL 84 11
CFS GAssist 87 8
CFS SVM 86 9
CFS RF 86 7
CFS PAM 89 7
PLSS BioHEL 84 7
PLSS GAssist 85 5
Breast cancer PLSS SVM 84 7
PLSS RF 89 5
PLSS PAM 88 7
RFS BioHEL 86 5
RFS GAssist 88 6
RFS SVM 80 17
RFS RF 89 5
RFS PAM 88 7
none BioHEL 88 5
10-fold cross-validation results obtained with BioHEL, SVM, RF and PAM on the
three microarray datasets using three feature selection methods (CFS, PLSS,
RFS); AVG = average accuracy, STDDEV = standard deviation; the highest
accuracies achieved with BioHEL and the best alternative method are both
shown in bold type for each dataset.
doi:10.1371/journal.pone.0039932.t002
Table 2. Cont.
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Prostate Cancer
On the prostate cancer dataset, the best prediction results with
BioHEL were reached without external feature selection, provid-
ing an average accuracy of 94% (10-fold CV), or when combining
BioHEL with the PLSS filter (avg. acc. 94%, LOOCV). Among
the alternative benchmark classifiers considered in this study
(SVM, RF and PAM, see Tables 2 and 3) only the PLS/PAM
combination achieved the same accuracy for 10-fold CV and the
CFS/RF combination reached a slightly higher accuracy for
LOOCV (95%). GAssist reached accuracies of at least 92% in
combination with all feature selection methods, but was outper-
formed by the best BioHEL models.
Similarly, in the cross-validation results reported in the
literature for this dataset only the methods by Shen et al.
(94.6%) [71] and Paul et al. (96.6%) [72] (see Table 4) obtained a
similar or slightly higher average accuracy than BioHEL. For
comparison, Shen et al. employ a singular value decomposition
(SVD) instead of feature selection, which includes more genes from
the original data than the maximum of 30 considered here for all
feature selection methods. This type of model can be more difficult
to interpret than decision rule models without feature transfor-
mation (unless the derived features can be linked to biological
processes). Paul et al. use the original features in their models, but
the average number of included genes also exceeds 30 features
(48.5). Thus, in comparison to state-of-the-art benchmark
classifiers and alternative approaches in the literature, BioHEL
reaches similar levels of accuracy, in spite of the simple nature of
its rule-base models, which facilitates the biological interpretation
for the experimenter.
Diffuse Large B-cell Lymphoma
On the DLBCL dataset, the highest average sample classifica-
tion accuracies of 95% (10-fold CV) and 94% (LOOCV) were
both obtained when using BioHEL without any feature selection.
Moreover, none of the parameter-optimized benchmark methods
reached higher accuracies, only the PLSS/SVM combination
provided the same accuracy as BioHEL. In the results reported in
the literature for this dataset (see Table 5), only the approach by
Wessels et al. [73] reached a slightly higher accuracy (96%) than
the best BioHEL models, but using a feature subset size of 80
genes, almost 3 times more than the maximum number of features
allowed into BioHel’s rules. GAssist provided accuracies in a
similar range of values as the other benchmark methods and
reached its best results (10-fold CV: 94%, LOOCV: 92%) in
combination with the PLSS filter.
A common problem in the classification of high-dimensional
data with small sample sizes is the high variance in cross-validation
error estimates, especially in LOOCV [65,74]. This observation
was also made on the three datasets considered in this study and
applies both to BioHEL and the alternative prediction methods.
Thus, in spite of the high average accuracy reached by some
method combinations, the lack of robustness still hinders the use of
these approaches in routine clinical application.
Table 3. Leave-one-out cross-validation results.
Dataset
Feature
Selection Classification AVG (%) STDDEV
CFS BioHEL 92 27
CFS GAssist 93 25
CFS SVM 89 31
CFS RF 95 22
CFS PAM 90 30
PLSS BioHEL 94 24
PLSS GAssist 92 27
Prostate cancer PLSS SVM 93 25
PLSS RF 93 25
PLSS PAM 93 25
RFS BioHEL 88 32
RFS GAssist 93 25
RFS SVM 89 31
RFS RF 91 29
RFS PAM 91 29
none BioHEL 92 27
CFS BioHEL 84 36
CFS GAssist 87 34
CFS SVM 88 32
CFS RF 87 34
CFS PAM 84 37
PLSS BioHEL 92 26
Diffuse large PLSS GAssist 92 27
B-cell lymphoma PLSS SVM 94 25
PLSS RF 90 31
PLSS PAM 86 35
RFS BioHEL 88 32
RFS GAssist 88 32
RFS SVM 90 31
RFS RF 92 27
RFS PAM 83 38
none BioHEL 94 25
CFS BioHEL 82 38
CFS GAssist 84 36
CFS SVM 84 37
CFS RF 84 36
CFS PAM 90 30
PLSS BioHEL 84 37
PLSS GAssist 84 36
Breast cancer PLSS SVM 81 39
PLSS RF 88 33
PLSS PAM 86 35
RFS BioHEL 82 39
RFS GAssist 85 36
RFS SVM 86 35
RFS RF 87 34
RFS PAM 88 32
none BioHEL 86 35
Leave-one-out cross-validation results obtained with BioHEL, SVM, RF and
PAM on the three microarray datasets using three feature selection methods
(CFS, PLSS, RFS); AVG = average accuracy, STDDEV = standard deviation; the
highest accuracies achieved with BioHEL and the best alternative are both
shown in bold type for each dataset.
doi:10.1371/journal.pone.0039932.t003
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Breast Cancer
For the breast cancer dataset, obtained from the Nottingham
Queen’s Medical Centre, the best average accuracies with
BioHEL were again obtained when using no external feature
selection, providing average accuracies of 88% (10-fold CV) and
86% (LOOCV). These results were similar to those of other
benchmark classifiers, with some methods being slightly superior
and some slightly inferior (the most successful approach was CFS/
PAM with 89% acc. for 10-fold CV and 90% acc. for LOOCV).
Importantly, independent of the feature selection and cross-
validation method, BioHEL always provided average accuracies of
at least 82% on the breast cancer data. GAssist again did not reach
BioHEL’s best performance, but provided robust accuracies of at
least 84% across all feature selection methods.
The lower accuracies achieved by all methods on the breast
cancer data in comparison to the performances of these methods
observed on the other datasets matches to previous observations
showing that the classification of breast cancer microarray samples
tends to be more difficult than the discrimination of gene array
samples for other cancer types [75]. Since the breast cancer
dataset considered here was obtained from a collaborating
institute, no external cross-validation results for alternative
methods are available in the literature, however, the dataset has
been published online (http://www.ebi.ac.uk/microarray-as/ae/
browse.html?keywords = E-TABM-576) and can freely be used for
comparative evaluation and biological analysis purposes.
On the whole, on all three datasets the BioHEL classification
models provided classification accuracies that were among the
highest in comparison to current benchmark classification
methods and other approaches from the literature. The similarity
between the averaged accuracies obtained from 10-fold CV and
LOOCV shows that these performance estimates are stable and do
not vary significantly with the chosen validation scheme (regarding
the variance of the accuracy across the cross-validation cycles, as
expected, lower variances are obtained when using the larger test
set sizes in 10-fold CV). Similarly, the comparison of prediction
and feature selection results across different dataset pre-processings
suggests that BioHEL’s performance is robust across a wide range
of pre-filtering settings (see Material S1 for detailed results and
discussion of the robustness analyses).
In order to objectively compare the classifiers across all datasets
and different feature selection methods, we additionally applied a
Friedman test [76,77] over the average classification accuracies
across all feature selection methods (once for 10-fold CV and once
for LOOCV). According to this statistical test, GAssist and the RF
method performed best for 10-fold CV and obtained the same
average rank (see Table 6) when using feature selection.
Interestingly, BioHEL obtained lower average ranks than these
methods when being combined with external feature selection, but
provided the overall highest accuracies without external attribute
selection. This result suggests that BioHEL exploits the informa-
tion content of features that are considered as insignificant by the
dedicated selection methods and thus avoids a performance
bottleneck resulting from the prior application of an external
selection approach.
For LOOCV, similar results were obtained as with 10-fold CV,
with the exception that RF achieved a better average rank than
GAssist with the second best rank. Again, BioHEL tends to obtain
lower average ranks in combination with external attribute
selection than the other approaches, but achieves the best overall
performance without external selection procedure.
Overall these results show that both systems (GAssist in
combination with feature selection and BioHEL without external
selection) not only generate compact and easy-to-interpret decision
Table 5. Comparison of prediction results from the literature
for the lymphoma dataset.
Author (year) Method AVG (%) Size
Wessels et al. [73] RFLD(10), Monte-Carlo CV 95.7 80
Liu et al. [126] MOEA+WV 93.5 6
Shipp et al. [41] SNR+WV, LOOCV 92.2 30
Goh et al. [127] PCC-SNR + ECF, LOOCV 91 10
Lecocke et al. [125] GA+SVM, LOOCV 90.2 **
GAGA+DLDA, LOOCV 89.8 **
GAGA+3-NN, LOOCV 86.3 **
Hu et al. [128] WWKNN, LOOCV 87.01 12
ECF, LOOCV 85.71 12
our study BioHEL, 10-fold CV 95 *30
BioHEL, LOOCV 94 *30
(*maximum no. of genes per base classifier in ensemble learning model;
**evaluation results averaged over feature subsets using different numbers of
genes).
doi:10.1371/journal.pone.0039932.t005
Table 6. Comparison of prediction methods.
Average ranks
method SVM RF PAM BioHEL GAssist
10-fold 3.8 2.3 3.1 3.4* 2.3
LOO 3.0 2.2 3.1 3.7* 3.0
Results of a Friedman test to compare prediction methods across different
datasets and feature selection methods (the best average ranks are shown in
bold typeface; *here only the results in combination with feature selection are
taken into account).
doi:10.1371/journal.pone.0039932.t006
Table 4. Comparison of prediction results from the literature
for the prostate cancer dataset.
Author (year) Method AVG (%) Size
T.K. Paul et al. [72] RPMBGA, LOOCV 96.6 48.5
Wessels et al. [73] RFLD(0), Monte-Carlo CV 93.4 14
Shen et al. [71] PLR, Monte-Carlo-CV (30
iterations)
94.6 ***
LSR, Monte-Carlo-CV (30
iterations)
94.3 ***
W Chu et al. [124] Gaussian processes, LOOCV 91.2 13
Lecocke et al. [125] SVM, LOOCV 90.1 **
DLDA, LOOCV 89.2 **
GAGA+3NN, LOOCV 88.1 **
our study BioHEL, 10-fold CV 94 *30
PLSS+BioHEL, LOOCV 94 *30
(*maximum no. of genes per base classifier in ensemble learning model;
**evaluation results averaged over feature subsets using different numbers of
genes; ***singular value decomposition used instead of classical feature
selection).
doi:10.1371/journal.pone.0039932.t004
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rules but also achieve the best or close-to-best performance in all
tested scenarios. Thus, BioHEL and GAssist enable experimenters
to benefit from the enhanced interpretability of a rule-based
learning approach without having to sacrifice performance in
comparison to other state-of-the-art approaches.
Across all methods, the overall memory requirements and the
runtimes for applying the trained models were similar and
negligibly small on a standard desktop machine (single applications
of an algorithm required a few minutes or less on a 2 GHz CPU).
The most time-consuming cross-validation experiment (combining
LOOCV with the 100-times BioHEL ensemble and repeating this
10 times for different random seeds) required less than one day.
Comparison of Feature Selection Results
When using feature selection prior to supervised classification,
the average accuracy often varies greatly with the choice of the
selection method, since the predictive performance does not only
depend on the inclusion of informative features, but can also be
affected negatively by the selection of redundant and irrelevant
features. To compare the three selection methods considered in
this study (CFS, RFS, PLSS), the Friedman test was applied to the
average classification accuracies (once for 10-fold CV and once for
LOOCV) across all datasets and all five prediction methods
(BioHEL, GAssist, SVM, RF and PAM).
In summary, according to a Holm-test applied after the
Friedman test, PLSS was significantly superior to CFS both for
10-fold CV (confidence level: 80%) and LOOCV (confidence
level: 90%), and also superior to RF for LOOCV (confidence level:
80%, no other significant differences were detected above this
confidence level). Similarly, PLSS obtained the best average ranks
in the Friedman test for both 10-fold CV and LOOCV (see
Table 7). These observations, showing that a univariate ranking
method outperformed a combinatorial filter and an embedded
selection method, could indicate that the feature independence
assumption behind the univariate approach is reasonably satisfied
for the most informative features, and justify the widespread
popularity of univariate approaches in microarray gene selection.
Relatively high performances of univariate selection strategies had
already been noted in a similar study on microarray data by
Wessels et al. [73], comparing other algorithms. However, an
alternative interpretation of these results might be that feature
dependencies detected by the multivariate selection methods were
false positives, resulting in a weaker predictive performance of
these approaches. Thus, if the independence assumption repre-
sents a good approximation for some of the most informative
features, or if multivariate methods fail to correctly capture the
dependence structure between different variables, a fast univariate
selection approach can be the method of choice for complex, high-
dimensional microarray data.
Literature Mining Analysis of Selected Genes - Results
To illustrate the utility of the analysis pipeline for biological
interpretation of the data and to compare the ensemble of the
external feature selection methods with BioHEL’s capacity to
directly identify informative features during the model generation,
an example literature mining was performed for the top-ranked
genes on each dataset (see Methods section). When considering
only genes chosen by at least two different selection methods
among the genes selected most frequently across the LOOCV
cycles, 11 genes were obtained for the prostate cancer dataset (see
Table 8 left), 10 genes for the lymphoma dataset (Table 9 left) and
18 genes for the breast cancer dataset (Table 10 left). To compare
these selection results against a ranking of genes according to the
frequency of their occurrence in the rule sets generated by the
BioHEL 100-times ensemble across all LOOCV cycles, the same
numbers of genes were selected from the top of these rankings for
each datasets (see Tables 8, 9 and 10, right side, the shared genes
detected as informative by both approaches are highlighted in bold
face).
The two gene rankings (ensemble feature selection and
BioHEL-based feature ranking) were validated externally using
literature mining in the PubMed database by computing the sum
of positive PMI scores (see Methods section) between the
standardized gene names from the rankings and the disease terms
from a controlled vocabulary matching to the three datasets
(‘‘prostatic neoplasms’’, ‘‘breast neoplasms’’ and ‘‘lymphoma, b-
cell’’). The same computation was repeated 100 times on matched-
size gene sets selected randomly from the genes on the
corresponding microarray platforms, and the histograms of these
random model PMI scores, as well as the scores achieved by the
ensemble feature selection (Ensemble FS) and BioHEL-based
feature ranking (BioHEL FR) are shown in Fig. 3, 4 and 5. To
quantify the relative performances of the methods, the p-value
significance score estimates obtained from these PMI scores are
listed in Table 11.
The table and the plots show that both the Ensemble FS and the
BioHEL FR method reached significant p-values ƒ 0.05 on the
prostate and the breast cancer dataset; however, neither of the two
approaches provided a significant p-value on the lymphoma data
(BioHEL FR p-value: 0.22, Ensemble FS p-value: 0.51). The lower
performance of the literature mining analysis on this dataset could
result from the lower number of available samples (77 samples in
relation to 102 for the prostate cancer study and 128 for the breast
cancer study), the high degree of class imbalance (58 diffuse large
b-cell lymphoma samples vs. 19 follicular lymphoma samples),
resulting in only 10 genes that were detected as significant by at
least two feature selection methods, and an overlap of zero
between the top-ranked genes obtained from Ensemble FS and
from BioHEL FR (see Table 9).
Regarding the relative performance of the gene selection
approaches, the text-mining analysis showed that in two out of
the three datasets, the lymphoma and the breast cancer dataset,
BioHEL FR reached lower p-values than Ensemble FS. Accord-
ingly, at least on some datasets, the BioHEL FR approach
provides superior results in terms of the PMI literature mining
scores in comparison to an ensemble of multiple selection
methods, even though BioHEL FR only requires the application
of a single algorithm.
Thus, the permutation-based text-mining analysis can provide
insights both on the reliability of gene selection results across
different datasets (in this case revealing a higher reliability
obtained on the prostate and breast cancer data in comparison
to the lymphoma data) and on the relative performance of the
gene selection methods.
Table 7. Comparison of feature selection methods.
Average ranks
method CFS PLSS RFS
10-fold 2.3 1.8 2.0
LOO 2.3 1.6 2.0
Results of a Friedman test to compare feature selection methods in terms of
classification accuracy across different datasets and prediction methods (the
best average ranks for each row are shown in bold typeface).
doi:10.1371/journal.pone.0039932.t007
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In addition to the automated text mining analysis, the functional
annotations of the top-ranked genes were also investigated by
manual inspection of the literature to identify specific associations
with the disease conditions of interest. Since an in-depth discussion
of the single genes selected by the two different approaches would
exceed the scope of this study, we focus mainly on the genes that
were selected by both the Ensemble FS and the BioHEL FR
approach.
For the prostate cancer dataset, 4 genes were found in the
intersection set of the two selection methods: Hepsin, Neural
epidermal growth factor-like 2 (nel-like 2), alpha-methylacyl-coa racemase
(AMACR) and adipsin. Annotations for these and all other genes on
the list were obtained from the Gene Cards web-service [78], the
DAVID functional annotation database [79] and from the
supplementary material of the microarray dataset. Canvassing of
the biomedical literature reveals that all these genes have either
known significant functional associations with prostate cancer, are
used as diagnostic markers or have previously been proposed as
new candidate markers.
Specifically, hepsin is a cell surface serine protease which has
been found to be significantly over-expressed in prostate cancer
[80–82] in other studies and which has also been proposed as a
prognostic biomarker [83,84]. However, there is no common
agreement on the function of hepsin; while some studies claim that
hepsin promotes prostate cancer progression [85], other studies
suggest that hepsin inhibits cell growth in prostate cancer cells
[86]. Neural epidermal growth factor-like 2 (nel-like 2, NELL2) is a
growth factor homologue that is believed to function as a
differentiation and regulation factor [87]. NELL2 has been
reported to be differentially expressed in benign prostatic
hyperplasia (BPH) [88], suggested as a mesenchymal regulator of
organogenesis and tumorigenesis [89] and used in a patented
diagnostic method for prostate cancer (US Patent App. 11/
519,892). The third candidate gene, Alpha-methylacyl-CoA racemase
(AMACR) codes for an enzyme with functional roles in bile acid
Table 9. List of high scoring genes for the lymphoma dataset.
Ensemble feature selection BioHEL feature ranking
Gene identifier Freq. Annotation Gene identifier Perc. Annotation
X02152_at 3 lactate dehydrogenase a (LDHA) X01060_at 6.6 Transferrin receptor protein 1
V00594_at 2 metallothionein 2a (MT2A) M63835_at 6.0 Immunoglobulin Gamma Fc receptor I
HG1980-HT2023_at 2 tubulin, beta 2c (TUBB2C) HG2090-HT2152_s_at 5.3 CD163 molecule
U63743_at 2 kinesin family member 2c (KIF2C) X02544_at 3.0 orosomucoid 1
X05360_at 2 cell division cycle 2, g1 to s and g2 to m (CDC2) U21931_at 1.9 fructose-1,6-bisphosphatase 1
M63379_at 2 clusterin D80008_at 1.7 GINS complex subunit 1 (Psf1 homolog)
M13792_at 2 adenosine deaminase (ADA) X65965_s_at 1.5 superoxide dismutase 2, mitochondrial
L19686_rna1_at 2 macrophage migration inhibitory factor (MIF) D13413_rna1_s_at 1.3 solute carrier family 36, member 2
D14662_at 2 peroxiredoxin 6 (PRDX6) L25876_at 1.2 cyclin-dependent kinase inhibitor 3
S73591_at 2 thioredoxin interacting protein (TXNIP) D78134_at 1.1 cold inducible RNA binding protein
List of genes that were chosen by at least two different selection methods among the 30 features selected most frequently on the lymphoma dataset. On this dataset,
the genes detected as informative by the Ensembl FS and the BioHEL FR did not overlap (see discussion in the literature mining analysis section).
doi:10.1371/journal.pone.0039932.t009
Table 8. List of high scoring genes for the prostate cancer dataset.
Ensemble feature selection BioHEL feature ranking
Gene identifier Freq. Annotation Gene identifier Perc. Annotation
37639_at 3 hepsin (transmembrane protease, serine 1) 32598_at 7.6 nel-like 2
32598_at 3 nel-like 2 914_g_at 4.0 transcriptional regulator ERG
41706_at 3 alpha-methylacyl-coa racemase (AMACR) 37639_at 3.4 hepsin (transmembrane protease, serine 1)
38634_at 3 retinol binding protein 1, cellular (CRBP1) 40282_s_at 2.0 complement factor d (adipsin)
37366_at 3 pdz and lim domain 5 (PDLIM5) 41817_g_at 1.5 caspase recruitment domain family, member 10
40282_s_at 2 complement factor d (adipsin) 35278_at 1.5 ribosomal protein S29
38087_s_at 2 s100 calcium binding protein a4 (S100A4) 41741_at 1.3 RNA-binding motif protein 3
41468_at 2 T cell receptor gamma (TCR-gamma) 32250_at 1.3 complement factor H
38827_at 2 anterior gradient 2 (AGR2) 32755_at 1.1 actin, alpha 2, smooth muscle, aorta
38406_f_at 2 prostaglandin d2 synthase 21kda (PTGDS) 41706_at 1.0 alpha-methylacyl-coa racemase (AMACR)
34840_at 2 we38g03.x1 homo sapiens cdna, 39 end 37331_g_at 0.9 aldehyde dehydrogenase 4 family, member A1
List of genes that were chosen by at least two different selection methods among the 20 features selected most frequently on the prostate dataset. The 4 genes
detected as informative by both the Ensembl FS and the BioHEL FR approach (hepsin, nel-like 2, AMACR and adipsin) are highlighted in bold face (see discussion in the
literature mining analysis section).
doi:10.1371/journal.pone.0039932.t008
Rule-Based Candidate Disease Gene Prioritization
PLoS ONE | www.plosone.org 10 July 2012 | Volume 7 | Issue 7 | e39932
biosynthesis and b-oxidation of branched-chain fatty acids [90]. It
has been identified to be significantly up-regulated in prostate
cancer based on different independent gene expression data sets
and has also been suggested as a biomarker for prostate cancer
diagnosis in various studies [84,91,92]. Adipsin is a specific gene for
adipocytes [93], cells specialized in storing energy as fat which
have also been suggested to affect the proliferation and differen-
tiation of epithelial cells. Culturing of adipocytes with a prostate
carcinoma cell line [94] has provided strong evidence that
adipocytes modulate the growth and cytokine expression of
prostate cancer cells (based on histological and immunohisto-
chemical assays and RT-PCR measurement of cytokine expres-
sion). Though the precise role of adipsin in cancer remains
unknown, its differential expression in cancer tissue has been
observed in several studies [95–97]. However, these findings might
also result from a general relationship between obesity and cancer,
since obesity is a risk factor for several cancers [98], including
prostate cancer, and adipsin expression is known to be impaired
both in acquired and genetic obesity [99].
On the lymphoma dataset, no overlap was found between
the top-ranked genes from the Ensemble FS and the BioHEL FR
approach. As mentioned before in the section on the automatic
literature mining analysis, a lower robustness of the feature
selection results on this dataset might result from the lower
number of available samples and the higher degree of class
imbalance in relation to the other datasets. However, when
inspecting the annotations for the top 3 genes on both ranking lists,
again strong functional associations with the disease condition
were found.
Lactate dehydrogenase A (LDHA), the only gene that was detected as
significant by all 3 selection methods in the Ensemble FS
approach, is known to have elevated expression levels after tissue
breakdown. For this reason, LDHA is already an established
marker to monitor cancer patients. Moreover, a relationship
Table 10. List of high scoring genes for the breast cancer dataset.
Ensemble feature selection BioHEL feature ranking
Gene identifier Freq. Annotation Gene identifier Perc. Annotation
GI_4503602-S 3 estrogen receptor 1 (ESR1) GI_37545993-S 0.7 Serpin A11 precursor
GI_14249703-S 3 RAS-like, estrogen-regulated, growth-inhibitor
(RERG)
GI_14249703-S 0.6 RAS-like, estrogen-regulated,
growth-inhibitor (RERG)
GI_16507967-S 3 potassium channel, subfamily K, member 15 (KCNK15)
GI_22779933-S 2 WD repeat membrane protein PWDMP (PWDMP) GI_23308560-S 0.6 RNA-binding protein 24
GI_42657473-S 2 Uncharacterized protein (C6orf115) GI_22779933-S 0.6 WD repeat membrane protein
PWDMP (PWDMP)
GI_7706686-S 2 Enah/Vasp-like (EVL) GI_16507967-S 0.5 potassium channel, subfamily K,
member 15 (KCNK15)
GI_40788002-S 2 proteasome (prosome, macropain) GI_22748948-S 0.4 IGF1R protein
activator subunit 4 (PSME4)
GI_33620752-S 2 hypothetical protein FLJ10876 (FLJ10876) GI_4507266-S 0.4 Stanniocalcin-2 precursor (STC-2)
GI_13236596-S 2 DDB1 and CUL4 associated factor 10 (WDR32) GI_29029609-A 0.4 pyrimidinergic receptor P2Y6,
G-protein coupled
GI_29029609-A 2 pyrimidinergic receptor P2Y6, G-protein coupled GI_4502798-S 0.4 Chondroadherin precursor
GI_37551139-S 2 hypothetical protein PRO2013 (PRO2013) Hs.501130-S 0.4 GDNF family receptor alpha 1
isoform b
GI_40255152-S 2 potassium channel tetramerisation GI_13236596-S 0.4 DDB1 and CUL4 associated factor
10 (WDR32)
domain containing 6 (KCTD6) GI_4503602-S 0.3 estrogen receptor 1 (ESR1)
GI_30410031-S 2 prostate-specific membrane antigen-like GI_42659577-S 0.3 uncharacterized protein KIAA1377
protein (PSMAL/GCP III)
GI_4503928-S 2 GATA binding protein 3 (GATA3), mRNA GI_29738585-S 0.3 GDNF family receptor alpha 1
(GFRA1, LOC143381)
transcript variant 1
GI_42659459-S 2 hypothetical gene supported by AK128810 (LOC399717) GI_21389370-S 0.3 ankyrin repeat domain 22
GI_29738585-S 2 GDNF family receptor alpha 1 (GFRA1, LOC143381) Hs.202515-S 0.3 calcium channel, voltage-
dependent, L type (CACNA1D)
transcript variant 1
GI_38455428-S 2 breast cancer membrane protein 11 (BCMP11),
mRNA
GI_18152766-S 0.3 synaptotagmin-like 4
(granuphilin-a) (SYTL4)
GI_22035691-A 2 GDNF family receptor alpha 1 (GFRA1) Hs.499414-S 0.3 Cluster 499414 (chr 10), unknown
function
transcript variant 2
List of genes that were chosen by at least two different selection methods among the 30 features selected most frequently on the breast cancer dataset. The 7 genes
detected as informative by both the Ensembl FS and the BioHEL FR approach are highlighted in bold face (see discussion in the literature mining analysis section).
doi:10.1371/journal.pone.0039932.t010
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between LDHA levels and the histological type and the tumor
mass of non-Hodgkin’s lymphomas has been investigated in the
literature [100]. Metallothionein 2a (MT2A), a gene that was selected
by 2 different methods in the Ensemble FS approach, codes for a
protein of the metallothionin family, which is involved in many
pathophysiological processes including protection against oxida-
tive damage, cell proliferation, drug and chemotherapy resistance
and cancer development [101]. Moreover, it has been shown that
malignant lymphoblasts of diffuse large B-cell lymphoma have
high metallothionein expression [102]. Similarly, tubulins like
TUBB2C are known to have higher expression levels in
proliferating cancer cells due to the microtubule formation in
these cells. These proteins are therefore often considered as targets
for anticancer drugs to inhibit the growth of cancer cells and there
expression levels have also been reported to be down-regulated in
treatments that induce apoptosis in lymphoma cells [103].
Transferrin receptor protein (TfR) 1, the top-ranked gene according
to the BioHEL FR approach, is required for the import of iron
into a cell by means of a receptor-mediated endocytic transport of
a transferrin-iron complex, but is also involved in the regulation of
cell growth. Elevated levels of TfR have been found in several
malignancies, and the membrane protein has been studied as a
promising target for the treatment of cancer using antibodies
[104]. Moreover, the expression of TfRs has previously been
reported to be correlated with survival and histological grading of
non-Hodgkin’s malignant lymphoma patients [105–107]. Immuno-
globulin gamma Fc receptor I (FCGR1A) is a receptor protein for
immunoglobulin antibodies, which are produced by the innate
immune system in response to viral and bacterial infections or
cancer cells. The gene is known to be expressed as part of the
immune response signature of follicular lymphoma [108] and
known to be part of a cluster of over-expressed immune system
related genes in B-cell lymphoma samples which are rich in T-cells
and histiocytes (immune cells capable of digesting foreign
substances) [109]. Interestingly, an approved drug against non-
Hodgkin lymphoma, Tositumomab, is known to bind to FGR1A,
although the intended target is the B-lymphocyte antigen CD20.
The hemoglobin scavenger receptor (Cluster of Differentiation 163,
CD163) protein, encoded by the gene ranked third by BioHEL
FR, is a receptor involved in clearance and endocytosis of
hemoglobin/haptoglobin complexes by macrophages. CD163 has
been proposed as a marker for tumour-infiltrating macrophages in
Hodgkin’s lymphoma, where high CD163 expression has been
observed to correlate with adverse outcome [110]. Moreover, it
has been suggested that CD163 might have an anti-inflammatory
role [111] and could have diagnostic value for monitoring
macrophage activation in inflammatory conditions, which are
considered to play a critical role in the tumour progression of
many cancers [112].
Figure 3. Comparison of text mining scores. Histogram of text mining scores for randomly chosen gene identifier subsets compared to scores
achieved by BioHEL and the ensemble feature selection (FS) approach (prostate cancer dataset).
doi:10.1371/journal.pone.0039932.g003
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For the breast cancer data, 7 genes were detected as
informative by both the Ensemble FS and the BioHEL FR
approach. We have recently evaluated one of these genes, RAS-like,
estrogen-regulated, growth-inhibitor (RERG), experimentally in a
collaborative study with the Queen’s Medical Centre in Notting-
ham by immunohistochemistry using tissue microarrays across
1140 invasive breast cancer samples [6]. The study confirmed that
the expression of RERG provides a sensitive marker for the
discrimination between the clinically relevant categories of luminal
and non-luminal breast cancer samples (see the approach by
Nielsen et al. for breast cancer subtype categorisation [113]).
Moreover, several significant correlations with already existing
markers of luminal differentiation were identified, including
positive correlations with the expression of the estrogen receptor,
luminal cytokeratins (CK19, CK18 and CK7/8), FOXA1 (p-
value = 0.004), androgen receptor, nuclear BRCA1, FHIT and cell
cycle inhibitors p27 and p21, and inverse associations with the
proliferation marker MIB1 (p-value = 0.005) and p53. More
importantly, strong RERG expression showed an association with
a longer breast cancer specific survival and distant metastasis free
interval in the whole patient cohort and these associations were
independent of other prognostic variables. These results match to
the high rankings this gene received by the computational gene
selection methods considered here. In the BioHEL FR approach,
RERG was ranked second, in the Ensemble FS approach it
belonged to the 3 only genes that were chosen as informative by all
three input selection methods (see Table 10).
A further gene with high ranks in both selection approaches is
estrogen receptor 1 (ESR1), a well-known breast cancer marker gene,
which encodes the estrogen receptor alpha (ER-a). In luminal
breast cancer samples, ER-a is known to be expressed in the
tumour cells (ER+ type), whereas it is not expressed in basal-like
samples (ER- type). The oestrogen hormone is well-known to
cause the growth of ER+ breast cancer cells, and some hormone
therapies are based on using anti-oestrogens as drugs against
corresponding forms of breast cancer.
A third top-ranked gene, potassium channel, subfamily K, member 15
(KCNK15, TASK-5), is a less obvious candidate gene and currently
unknown in oncogenesis. However, KCNK15 has been found to
be silenced by hypermethylation of the promotor region in many
tumours [114]. The gene encodes a two-pore potassium channel
protein, which corresponds to findings for other ion channels, like
the Ca2+ channel CACNA1G and the Na+ channel SLC5A8 with
putative tumour suppressive function, which have already been
reported to be hypermethylated in different cancers [115,116].
Thus this gene/protein might be a promising target for future
investigations.
Another membrane protein selected by both approaches is the
WD repeat membrane protein (PWDMP, WDR19). WD-repeat proteins
form a family of structurally related proteins that participate in
Figure 4. Comparison of text mining scores. Histogram of text mining scores for randomly chosen gene identifier subsets compared to scores
achieved by BioHEL and the ensemble feature selection (FS) approach (lymphoma cancer dataset).
doi:10.1371/journal.pone.0039932.g004
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several cellular functions, including vesicle formation, vesicular
trafficking, transmembrane signaling and mRNA modification
[117]. In a previous breast cancer study, WDR19 has been
identified to be differentially expressed between carcinoma cells
with similar morphology to healthy cells and cells with deviating,
irregular morphology [118]. However, so far, WDR19 has only
been implicated in other cancer types, in particular prostate cancer
[119]. Interestingly, a further WD repeat-containing protein was
selected by both approaches, WDR32 (WD repeat-containing protein
32), also known as DDB1 and CUL4 associated factor 10. WDR32 has
been found to be differentially expressed in breast cancer cells in
several studies, as reported in the Genes-to-Systems Breast Cancer
(G2SBC) database [120].
The 6th gene in the intersection set of the ranking lists is G-
protein coupled pyrimidinergic receptor P2Y6, belonging to the group of
P2Y receptors that respond to purine and pyrimidine nucleotides.
P2Y6 expression has been shown to be deregulated in cases of
altered progestin responsiveness due to changes in the expression
of progesterone receptor isoforms, which are known to occur in
breast cancer cells [121]. Moreover, in 2003 a patent application
has been filed for a method to detect pre-neoplastic and neoplastic
states based on P2Y expression levels (US Patent App. 10/
450,205).
Finally, the gene that occurs most frequently in different
transcript variants as top-ranked in both selection methods is
GDNF family receptor alpha 1 (GFRA1), which occurs in the transcript
variants 1 and 2 and the isoform b version. The Glial cell line-
derived neurotrophic factor (GDNF) which binds to the receptor
GFRA1 is known to play an important role in differentiation and
the control of neuron survival. It has also been suggested to
function as a component of the inflammatory response in breast
cancers, and an experimental study using a breast cancer tissue
microarray has shown that GFRA1 transcripts are over-expressed
in invasive breast carcinomas, and in particular in hormone
receptor–positive (ER+ and PR+) tumors [122].
In summary, all genes appearing in both lists of top-ranked
genes from different selection approaches have either putative or
known functional associations with the corresponding cancer type.
Figure 5. Comparison of text mining scores. Histogram of text mining scores for randomly chosen gene identifier subsets, compared to scores
achieved by BioHEL and the ensemble feature selection (FS) approach (breast cancer dataset).
doi:10.1371/journal.pone.0039932.g005
Table 11. Literature mining significance scores.
Dataset Ensemble FS (p-value) BioHEL FR (p-value)
Prostate 0.00 0.05
Lymphoma 0.51 0.22
Breast 0.02 0.03
doi:10.1371/journal.pone.0039932.t011
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Although this does not imply that all high-scoring genes and their
corresponding products are suitable markers for the diagnosis or
monitoring of cancer diseases, both the automated literature
mining analysis and the manual inspection of the functional
annotations of the top-ranked genes confirm the utility of these
selection methods for identifying and prioritizing putative markers,
and for the biological interpretation of the data.
While classical gene prioritization methods are based on a single
feature selection method and a single confidence measure [123], the
approaches employed here use either information from multiple
selection methods or multiple prediction models given by ensembles
of BioHEL rule sets. Moreover, the robustness of the selection across
multiple cross-validation cycles is taken into account.
Finally, since the lists of high-scoring candidate genes which
were detected by multiple feature selection methods are confined
to relatively small sets of attributes, it is feasible to apply more
sensitive experimental approaches to study single genes and
proteins, e.g. using a quantitative polymerase chain reaction
(qPCR) or immunohistochemistry on tissue microarrays, as
illustrated by the successful validation of RERG gene expression
as a marker for luminal-like breast cancer samples.
Conclusion
In this paper, we have evaluated the rule-based, evolutionary
machine learning systems BioHEL and GAssist for supervised
microarray sample classification. Empirical results on three public
microarray datasets using three feature selection methods and two
external cross-validation schemes show that both methods reach
comparable accuracies to current state-of-the-art prediction
methods for gene array data, and achieve the best or close-to-
best performance depending on the setting: BioHEL achieves the
highest overall accuracies when being applied without external
feature selection, whereas GAssist tends to outperform other
methods when being applied in combination with feature
selection. These results are corroborated by comparisons across
multiple types of feature selection methods, as well as by
comparisons to other methods in the literature.
As an added value, in contrast to other state-of-the-art
benchmark methods, the prediction models generated by BioHEL
and GAssist are based on easily interpretable if-then-else-rules.
These benefits in terms of model interpretability are for example
highlighted by the compact rule set obtained for the prostate
cancer dataset shown in Fig. 2. Apart from indicating the
relevance of six used genes as putative biomarkers, the first two
conjunctive rules also point to potential associations between their
included genes. Corresponding genes which are frequently
selected as informative features in rule sets across different cross-
validation cycles and different ensemble base classifiers provide
robust and informative predictors with regard to the outcome
attribute. In this context, using a high number of base models
combined to an ensemble can even be beneficial for data
interpretation due to the variance-reducing effects of ensemble
learning [62] which result in more robust statistics on the
importance of single features in the predicates of the decision
rules. This concept matches well with the results of both the
automated text-mining analysis and the manual inspection of the
literature, showing that in gene rankings obtained from BioHEL
the top-ranked genes have all known or putative functional
associations to the studied cancer diseases.
As a by-product of our experiments, we also compared the
performance of different types of attribute selection methods: A
univariate selection approach (PLSS [46]), a combinatorial filter
(CFS [36]) and an embedded approach (RFS [38]). The
combination of the predictors with the fast univariate PLSS
approach provided unexpectedly high accuracies in comparison to
the more complex CFS and RFS methods, however, PLSS lacks
the adaptivity of the CFS approach, which is capable of
automatically estimating the optimal number of selected features.
Overall, the classification results obtained for different feature
selection methods across all prediction methods and all the original
datasets (and also the different pre-processing variants presented in
the Material S1) suggest that the user should not rely on a single
selection approach as a general method of choice. Instead, we
recommend to use both the CFS approach, as the most adaptive
multivariate approach, and the univariate PLSS approach, as the
most successful approach for settings in which all or most of the
selected features are univariately significant. Given the cross-
validation results for both of these selection methods on the
available labelled training data, the user can then choose the
approach that provides the best performance in this validation.
Moreover, applying both the CFS and PLSS method and
comparing the results has the added benefit of enabling a
distinction between features selected as univariately or multi-
variately significant.
Possible future extensions for the machine learning systems
BioHEL and GAssist include integrating prior clinical or biological
knowledge into the analysis and directly combining the system
with automated literature mining tools to better exploit the
information content of the generated models. On the whole, the
performance reached in comparison to other benchmark predic-
tors and the benefits in terms of interpretability and robust ranking
of genes show that rule-based evolutionary machine learning
algorithms can be profitably applied for the supervised analysis of
microarray data.
Supporting Information
Material S1 Supplementary information on datasets
and robustness statistics. The Supplementary Material
contains details on the source and normalization for each
microarray dataset used in this study, cross-validation results for
different dataset pre-processing methods and a robustness analysis
for the feature selection methods.
(PDF)
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